20878-52-8

Usage

Structure

Benzamide derivative with a trifluoromethyl group attached to a phenyl ring

Molecular Weight

286.25 g/mol

Application

Used in various research and biochemical applications

Biological/Pharmacological Activities

Potential biological and pharmacological activities

Significance of Trifluoromethyl Group

Modulates metabolic stability and lipophilicity of drug candidates

Utility in Medicinal Chemistry

Valuable tool for medicinal chemistry

Potential Applications

Development of pharmaceuticals and study of target-specific drugs

Upstream product

• 349-55-3 5-(trifluoromethyl)-m-anisidine 
• 610-14-0 2-nitrobenzyl chloride 
• 552-16-9 ortho-nitrobenzoic acid 
• 304884-94-4 2-nitro-N-(3-trifluoromethylphenyl)benzamide 
• 118-48-9 isatoic anhydride 
• 98-16-8 3-trifluoromethylaniline 
• 68790-38-5 2-(tert-butyloxycarbonylamino)benzoic acid 

Downstream Products

• 133040-82-1 2-[2-(5-Bromo-1H-indol-3-yl)-ethyl]-3-(3-trifluoromethyl-phenyl)-3H-quinazolin-4-one 
• 310423-02-0 4-oxo-3-(3-trifluoromethyl-phenyl)-3,4-dihydro-quinazoline-2-carboxylic acid ethyl ester 
• 1429192-21-1 2-(5-methylthiophen-2-yl)-3-(3-(trifluoromethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel benodanil-heterocyclic carboxamide hybrids as a potential succinate dehydrogenase inhibitors

In order to discover new antifungal agents, twenty novel benodanil-heterocyclic carboxamide hybrids were designed, synthesized, and characterized by 1H NMR and HRMS. In vitro, their antifungal activities against four phytopathogenic fungi were

MODULATORS OF THE RELAXIN RECEPTOR 1

Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardi

Copper-catalyzed radical methylation/C-H amination/oxidation cascade for the synthesis of quinazolinones

A copper-catalyzed radical methylation/sp3 C-H amination/oxidation reaction for the facile synthesis of quinazolinone was developed. In this cascade reaction, dicumyl peroxide acts not only as a useful oxidant but also as an efficient methyl source. Notably, a methyl radical, generated from peroxide, was confirmed by electron paramagnetic resonance for the first time.

Discovery of potent vascular endothelial growth factor receptor-2 inhibitors

Substantial evidence over the last decades has implicated uncontrolled angiogenesis with various pathological states, including cancer. Vascular endothelial growth factor (VEGF) plays a critical role in its regulation. Because the tyrosine kinase VEGF rec

Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor

Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide (18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 ± 0.05 μM, COX-2 IC50 = 210 ± 10 μM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.

ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE

The present invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more

N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors

Described are compounds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10-(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of

Anthranilic acid amides: A novel class of antiangiogenic VEGF receptor kinase inhibitors

Two readily synthesized anthranilamide, VEGF receptor tyrosine kinase inhibitors have been prepared and evaluated as angiogenesis inhibitors. 2-[(4-Pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide (5) and N-3-isoquinolinyl-2-[(4-pyridinylmethyl